Dr Lalchandani Labs Ltd
₹ 18.0
-3.90%
22 Nov
- close price
About
Incorporated in 2011, Dr. Lalchandani Labs Ltd is in the business of running laboratories
for pathological investigations[1]
Key Points
- Market Cap ₹ 7.80 Cr.
- Current Price ₹ 18.0
- High / Low ₹ 28.9 / 0.00
- Stock P/E 9.07
- Book Value ₹ 22.4
- Dividend Yield 0.00 %
- ROCE -2.68 %
- ROE -8.23 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 0.80 times its book value
Cons
- Promoter holding has decreased over last quarter: -3.60%
- The company has delivered a poor sales growth of -1.77% over past five years.
- Company has a low return on equity of -4.80% over last 3 years.
- Company has high debtors of 357 days.
- Working capital days have increased from 271 days to 402 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|
2.79 | 5.26 | 6.10 | 9.78 | 11.28 | 5.04 | 4.81 | 4.21 | |
2.17 | 4.06 | 4.84 | 7.54 | 8.81 | 4.95 | 4.59 | 2.63 | |
Operating Profit | 0.62 | 1.20 | 1.26 | 2.24 | 2.47 | 0.09 | 0.22 | 1.58 |
OPM % | 22.22% | 22.81% | 20.66% | 22.90% | 21.90% | 1.79% | 4.57% | 37.53% |
0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 1.40 | 0.24 | |
Interest | 0.16 | 0.14 | 0.18 | 0.35 | 0.60 | 0.99 | 0.38 | 0.33 |
Depreciation | 0.13 | 0.35 | 0.42 | 0.52 | 0.59 | 0.66 | 0.62 | 0.57 |
Profit before tax | 0.36 | 0.72 | 0.66 | 1.37 | 1.28 | -1.56 | 0.62 | 0.92 |
Tax % | 25.00% | 26.39% | 28.79% | 26.28% | 28.12% | 0.00% | 0.00% | |
0.26 | 0.53 | 0.47 | 1.01 | 0.93 | -1.56 | 0.62 | 0.86 | |
EPS in Rs | 0.89 | 1.22 | 1.08 | 2.33 | 2.15 | -3.60 | 1.43 | 1.99 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -2% |
3 Years: | -21% |
TTM: | -23% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 226% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | -3% |
3 Years: | -23% |
1 Year: | -49% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 0% |
3 Years: | -5% |
Last Year: | -8% |
Balance Sheet
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|
Equity Capital | 2.93 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 |
Reserves | 0.40 | 3.73 | 4.21 | 5.22 | 6.15 | 4.59 | 5.21 | 5.36 |
1.88 | 0.90 | 1.76 | 4.04 | 5.15 | 6.40 | 3.48 | 3.63 | |
1.00 | 1.18 | 1.63 | 1.61 | 2.49 | 2.40 | 1.97 | 2.05 | |
Total Liabilities | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 14.99 | 15.37 |
2.06 | 3.28 | 3.47 | 5.24 | 5.75 | 5.39 | 3.99 | 3.79 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.41 | 0.27 |
3.91 | 6.62 | 8.22 | 9.72 | 12.13 | 12.09 | 10.59 | 11.31 | |
Total Assets | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 14.99 | 15.37 |
Cash Flows
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
0.58 | -0.45 | -0.10 | 1.19 | 2.01 | 0.00 | -0.22 | |
-1.29 | -1.95 | -0.53 | -2.26 | -1.53 | -0.20 | 1.00 | |
1.57 | 3.51 | 0.85 | 1.71 | 0.16 | -0.23 | -1.59 | |
Net Cash Flow | 0.85 | 1.12 | 0.23 | 0.64 | 0.64 | -0.43 | -0.81 |
Ratios
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
Debtor Days | 149.14 | 126.99 | 199.25 | 148.54 | 136.55 | 359.93 | 356.65 |
Inventory Days | 167.03 | 233.36 | 158.70 | 68.75 | 191.07 | 458.51 | 255.15 |
Days Payable | 426.86 | 406.89 | 355.48 | 97.06 | 175.15 | 404.21 | 217.94 |
Cash Conversion Cycle | -110.69 | -46.54 | 2.47 | 120.23 | 152.47 | 414.23 | 393.86 |
Working Capital Days | 168.76 | 170.70 | 209.43 | 132.86 | 123.93 | 287.51 | 402.18 |
ROCE % | 12.14% | 8.72% | 14.40% | 12.87% | -3.68% | -2.68% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
14 Nov - Resignation of Company Secretary Mrs. Namita Anand.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 28 Oct
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 28 Oct
-
Board Meeting Outcome for Unaudited Financial Results For The Half Year Ended September 30, 2024
14 Oct - Board approved unaudited financial results for H1 2024.
- Unaudited Financial Results For The Half Year Ended September 30, 2024 14 Oct
Business Overview:[1][2][3]
DLLL is a NABL accredited company with 5 Self-sufficient Labs and 15 collection centers across Delhi/NCR. It is empaneled for CGHS (South, North and East Block), DJB, MCD, DDA etc. and provides diagnostic and related healthcare tests and services. Company owns, runs laboratories for carrying out pathological investigations of various branches of Bio-Chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Virology, Cytology, other pathological Investigations and Immunoassay, Immuno-Histochemistry, Molecular Pathology, DNA & Genetic Testing etc.